CureVac Says In Talks With Potential Vaccine Development Partners
“The location of the partner does not play a role. We are looking for a partner who is best placed to support us,” Chief Executive Franz-Werner Haas told a media briefing.
He said that a global infrastructure to monitor possible side effects after market launch was among the aspects to be addressed by a partner, but he added that CureVac may also outsource this task to a service provider.
Haas said the group was close to launching a Phase III trial with about 36,000 participants to find out whether its vaccine can prevent infections and that it plans to produce 300-400 million vaccine doses next year.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor